Liangtao Ye

No. 107 Yanjiang Road
Guangzhou, 510120, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Prognostic Significance of Elevated Platelet Count (>200 x 10^9 per L) in BCLC Stages B and C of Hepatocellular Carcinoma: A Retrospective Multicenter Analysis.

Prognostic Significance of Elevated Platelet Count (>200 x 10^9 per L) in BCLC Stages B and C of Hepatocellular Carcinoma: A Retrospective Multicenter Analysis.

Journal: Journal of hepatocellular carcinoma

Published: December 31, 2024

Efficacy of CDK4/6 Inhibition in colorectal cancer and the role of p16 expression in predicting drug resistance.

Efficacy of CDK4/6 Inhibition in colorectal cancer and the role of p16 expression in predicting drug resistance.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: December 07, 2024

Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real-World Analysis of the IMMUreal Cohort.

Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real-World Analysis of the IMMUreal Cohort.

Journal: Alimentary pharmacology & therapeutics

Published: September 25, 2024

Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.

Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.

Journal: JHEP reports : innovation in hepatology

Published: October 04, 2023

Concomitant Irradiation to Checkpoint Inhibitor Therapy of Hepatocellular Carcinoma Patients: A Systematic Retrospective, Single-Center Analysis.

Concomitant Irradiation to Checkpoint Inhibitor Therapy of Hepatocellular Carcinoma Patients: A Systematic Retrospective, Single-Center Analysis.

Journal: Oncology research and treatment

Published: May 12, 2023

The inhibition of YAP Signaling Prevents Chronic Biliary Fibrosis in the Abcb4-/- Model by Modulation of Hepatic Stellate Cell and Bile Duct Epithelium Cell Pathophysiology.

The inhibition of YAP Signaling Prevents Chronic Biliary Fibrosis in the Abcb4-/- Model by Modulation of Hepatic Stellate Cell and Bile Duct Epithelium Cell Pathophysiology.

Journal: Aging and disease

Published: January 21, 2023

Corrigendum to "Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-related manner" [Canc. Lett. 371 (2016) 354-365].

Corrigendum to "Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-related manner" [Canc. Lett. 371 (2016) 354-365].

Journal: Cancer letters

Published: August 08, 2022

TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.

TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.

Journal: Cancers

Published: August 02, 2022

Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management.

Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management.

Journal: Liver cancer

Published: June 07, 2022

Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis.

Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis.

Journal: Journal of hepatocellular carcinoma

Published: December 30, 2021

Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC.

Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC.

Journal: Hepatology (Baltimore, Md.)

Published: December 21, 2021

Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.

Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.

Journal: Digestive diseases (Basel, Switzerland)

Published: June 07, 2021

Showing 1-12 of 23

Last Updated: 09/26/2026